Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Kamya Sankar

Title(s)Hs Assistant Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Circulating Inflammatory and Mitochondrial Biomarkers Associated with Cachexia in Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2026 Feb 17; 18(4). Sankar K, Kazemian E, Lorona N, Cruz-Hernández CD, Bryant AK, Mastali M, Merchant AA, Van Eyk J, Reckamp KL, Iyengar P, Bhowmick NA, Figueiredo JC. PMID: 41749907; PMCID: PMC12939877.
      View in: PubMed   Mentions:
    2. Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States. Adv Ther. 2026 Jan; 43(1):214-230. Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S. PMID: 41222788; PMCID: PMC12858494.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. The Expanding Landscape of Next-Generation EGFR Tyrosine Kinase Inhibitors: Have We Reached Capacity? J Thorac Oncol. 2025 Nov; 20(11):1569-1572. Sankar K, Waissengrin B, Reckamp KL. PMID: 41203379.
      View in: PubMed   Mentions:    Fields:    
    4. Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer. Sci Rep. 2025 Oct 13; 15(1):35597. Chan AA, Sankar K, Reckamp KL, Díaz B, Lee DJ. PMID: 41083501; PMCID: PMC12518850.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19; 16(1):7717. Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. PMID: 40830141; PMCID: PMC12365225.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    6. de novo metastases in patients with primary colorectal cancer: a Surveillance, Epidemiology, and End Results analysis. Cancer Causes Control. 2025 Sep; 36(9):937-946. Loroña NC, Sankar K, Stern MC, Schmit SL, Figueiredo JC. PMID: 40252135; PMCID: PMC12380965.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer. Drug Resist Updat. 2025 Jul; 81:101237. Thiruvalluvan M, Billet S, Liu Z, Lownik J, Waissengrin B, Kim H, Villamejor AL, Milshteyn L, Li X, Gayhart M, Araña M, Sankar K, Posadas EM, Lopategui J, You S, Reckamp KL, Bhowmick NA. PMID: 40090182.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    8. Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed? Lancet. 2025 Mar 08; 405(10481):757-759. Sankar K, Reckamp KL. PMID: 40057331.
      View in: PubMed   Mentions: 2     Fields:    
    9. DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer. Lung Cancer. 2025 Mar; 201:108444. Sankar K, Mercer J, Jaeger EB, Godden J, Williams E, Thompson MA, Patel SA, Figueiredo JC, Weinberg F, Reckamp KL. PMID: 39961190.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    10. Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer. Front Cardiovasc Med. 2024; 11:1485033. Le JN, Gasho JO, Peony O, Singh A, Silos KD, Kim S, Nguyen AT, Kamrava M, Mirhadi A, Hakimian B, Reckamp KL, Sankar K, Mak RH, Nikolova AP, Atkins KM. PMID: 39741660; PMCID: PMC11685755.
      View in: PubMed   Mentions: 1  
    11. Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study. Lancet Oncol. 2024 Dec; 25(12):1666-1676. Miller S, Jiang R, Schipper M, Fritsche LG, Strohbehn G, Wallace B, Brinzevich D, Falvello V, McMahon BH, Zamora-Resendiz R, Ramnath N, Dai X, Sankar K, Edwards DM, Allen SG, Yoo S, Crivelli S, Green MD, Bryant AK. PMID: 39551068; PMCID: PMC12169339.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System. Cancer Med. 2024 Nov; 13(21):e70379. Miller SR, Schipper M, Fritsche LG, Jiang R, Strohbehn G, Ötles E, McMahon BH, Crivelli S, Zamora-Resendiz R, Ramnath N, Yoo S, Dai X, Sankar K, Edwards DM, Allen SG, Green MD, Bryant AK. PMID: 39508134; PMCID: PMC11541111.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    13. Emerging Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2024 Sep 18; 25(18). Liu L, Soler J, Reckamp KL, Sankar K. PMID: 39337530; PMCID: PMC11432526.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    14. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. J Thorac Oncol. 2025 Jan; 20(1):109-118. Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. PMID: 39260522; PMCID: PMC12874404.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Development and validation of a biomarker index for HCC treatment response. Hepatol Commun. 2024 07 01; 8(7). Liang J, Li PY, Norman J, Lauzon M, Yeo YH, Trivedi H, Ayoub WS, Kuo A, Friedman ML, Sankar K, Gong J, Osipov A, Hendifar A, Todo T, Kim I, Voidonikolas G, Brennan TV, Wisel SA, Steggarda J, Kosari K, Saouaf R, Nissen N, Yao F, Mehta N, Yang JD. PMID: 38896084; PMCID: PMC11186807.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Pragmaticism in Cancer Clinical Trials. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e100040. Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, Herbst RS, Gray JE, Reckamp KL. PMID: 38771997.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun; 19(6):928-940. Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. PMID: 38278303.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    18. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States. Gastro Hep Adv. 2024; 3(2):230-237. Kaur B, Yeo YH, Liang J, Luu M, Ayoub W, Kuo A, Trivedi H, Sankar K, Gong J, Hendifar A, Osipov A, Kosari K, Nissen N, Noureddin M, Singal AG, Yang JD. PMID: 39129956; PMCID: PMC11308067.
      View in: PubMed   Mentions: 2  
    19. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):963-970. Edwards DM, Sankar K, Alseri A, Jiang R, Schipper M, Miller S, Dess K, Strohbehn GW, Elliott DA, Moghanaki D, Ramnath N, Green MD, Bryant AK. PMID: 37793573.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    20. Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma. Am J Gastroenterol. 2023 12 01; 118(12):2201-2211. Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sankar K, Gong J, Hendifar A, Osipov A, Friedman ML, Lipshutz HG, Steinberger J, Kosari K, Nissen N, Abou-Alfa GK, Singal AG, Yang JD. PMID: 37561061.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    21. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024 Jan; 30(1):1-15. Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, Koltsova EK, Yang JD. PMID: 37482076; PMCID: PMC10776289.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    22. Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers. Transl Gastroenterol Hepatol. 2023; 8:29. Sankar K, Pearson AN, Worlikar T, Perricone MD, Holcomb EA, Mendiratta-Lala M, Xu Z, Bhowmick N, Green MD. PMID: 37601739; PMCID: PMC10432235.
      View in: PubMed   Mentions: 9  
    23. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2023 Apr 21; 24(8). Ji JH, Ha SY, Lee D, Sankar K, Koltsova EK, Abou-Alfa GK, Yang JD. PMID: 37108802; PMCID: PMC10144688.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    24. TOPAZ-1: a new standard of care for advanced biliary tract cancers? Immunotherapy. 2023 05; 15(7):473-476. Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. PMID: 36950948.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    25. Approach to systemic therapy in advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022 Dec; 11(6):931-934. Sankar K, Gong J, Kosari K, Nissen NN, Yang JD. PMID: 36523939; PMCID: PMC9745627.
      View in: PubMed   Mentions: 1  
    26. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations. Expert Opin Pharmacother. 2022 Oct; 23(14):1569-1575. Strohbehn GW, Sankar K, Qin A, Kalemkerian GP. PMID: 36217844.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    27. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. Eur J Cancer. 2022 08; 171:55-63. Bryant AK, Sankar K, Zhao L, Strohbehn GW, Elliott D, Moghanaki D, Kelley MJ, Ramnath N, Green MD. PMID: 35704975; PMCID: PMC10508975.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    28. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. Int J Radiat Oncol Biol Phys. 2022 07 15; 113(4):752-758. Bryant AK, Sankar K, Strohbehn GW, Zhao L, Daniel V, Elliott D, Ramnath N, Green MD. PMID: 35450753; PMCID: PMC9246927.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    29. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):60-65. Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Daniel V, Ramnath N, Green MD. PMID: 35115216; PMCID: PMC9018488.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    30. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers (Basel). 2022 Jan 26; 14(3). Sankar K, Bryant AK, Strohbehn GW, Zhao L, Elliott D, Moghanaki D, Kelley MJ, Ramnath N, Green MD. PMID: 35158881; PMCID: PMC8833364.
      View in: PubMed   Mentions: 24  
    31. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2022 01; 163:35-41. Bryant AK, Sankar K, Strohbehn GW, Zhao L, Elliott D, Qin A, Yentz S, Ramnath N, Green MD. PMID: 34896803; PMCID: PMC8770596.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    32. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 03 01; 4(3):e210980. Waninger JJ, Ma VT, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Sankar K, Ramnath N, Lao C, Sussman JB, Fecher L, Alva A, Green MD. PMID: 33687443; PMCID: PMC7944385.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    33. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. Eur J Heart Fail. 2018 04; 20(4):677-686. Vaduganathan M, Cheema B, Cleveland E, Sankar K, Subacius H, Fonarow GC, Solomon SD, Lewis EF, Greene SJ, Maggioni AP, Böhm M, Zannad F, Butler J, Gheorghiade M. PMID: 29143416; PMCID: PMC6676477.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    Kamya's Networks
    Concepts (96)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California